Gabrielle E Hatton1,2,3, Kayla D Isbell1,2,3, Hanne H Henriksen4, Jakob Stensballe4,5, Martin Brummerstedt4, Pär I Johansson4, Lillian S Kao1,2,3, Charles E Wade1,3. 1. Division of Acute Care Surgery, Department of Surgery, McGovern Medical School at UTHealth, Houston, Texas. 2. Center for Surgical Trials and Evidence-based Practice, McGovern Medical School at UTHealth, Houston, Texas. 3. Center for Translational Injury Research, Houston, Texas. 4. Section for Transfusion Medicine, Capital Region Blood Bank, University of Copenhagen, Copenhagen, Denmark. 5. Department of Anaesthesia and Trauma Centre, Centre of Head and Orthopedics, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Abstract
INTRODUCTION: Nearly half of severely injured patients suffer acute kidney injury (AKI), but little is known about its pathogenesis or optimal management. We hypothesized that endothelial dysfunction, evidenced by elevated systemic soluble thrombomodulin (sTM) and syndecan-1, would be associated with higher incidence, worsened severity, and prolonged duration of AKI after severe trauma. METHODS: A single-center cohort study of severely injured patients surviving ≥24 h from 2012 to 2016 was performed. Arrival plasma sTM and syndecan-1 were measured by ELISA. Outcomes included 7-day AKI incidence, stage, and prolonged AKI ≥2 days. The Kidney Disease Improving Global Outcomes guidelines were used for AKI diagnosis and staging. Univariate and multivariable analyses were performed. RESULTS: Of 477 patients, 78% were male. Patients had a median age of 38 (interquartile ranges [IQR] 27-54) and injury severity score of 17 (IQR 10-26). AKI developed in 51% of patients. Those with AKI were older and displayed worse arrival physiology. Patients with AKI had higher plasma levels of syndecan-1 (median 34.9 ng/mL vs. 20.1 ng/mL) and sTM (6.5 ng/mL vs. 4.8 ng/mL). After adjustment, sTM and syndecan-1 were both associated with higher AKI incidence, worse AKI severity, and prolonged AKI duration. The strength and precision of the association of sTM and these outcomes were greater than those for syndecan-1. A sensitivity analysis excluding patients with AKI on arrival demonstrated the same relationship. CONCLUSIONS: Elevated sTM and syndecan-1, indicating endothelial dysfunction, were associated with higher incidence, worsened severity, and prolonged duration of AKI after severe trauma. Treatments that stabilize the endothelium hold promise for AKI treatment in severely injured patients.
INTRODUCTION: Nearly half of severely injured patients suffer acute kidney injury (AKI), but little is known about its pathogenesis or optimal management. We hypothesized that endothelial dysfunction, evidenced by elevated systemic soluble thrombomodulin (sTM) and syndecan-1, would be associated with higher incidence, worsened severity, and prolonged duration of AKI after severe trauma. METHODS: A single-center cohort study of severely injured patients surviving ≥24 h from 2012 to 2016 was performed. Arrival plasma sTM and syndecan-1 were measured by ELISA. Outcomes included 7-day AKI incidence, stage, and prolonged AKI ≥2 days. The Kidney Disease Improving Global Outcomes guidelines were used for AKI diagnosis and staging. Univariate and multivariable analyses were performed. RESULTS: Of 477 patients, 78% were male. Patients had a median age of 38 (interquartile ranges [IQR] 27-54) and injury severity score of 17 (IQR 10-26). AKI developed in 51% of patients. Those with AKI were older and displayed worse arrival physiology. Patients with AKI had higher plasma levels of syndecan-1 (median 34.9 ng/mL vs. 20.1 ng/mL) and sTM (6.5 ng/mL vs. 4.8 ng/mL). After adjustment, sTM and syndecan-1 were both associated with higher AKI incidence, worse AKI severity, and prolonged AKI duration. The strength and precision of the association of sTM and these outcomes were greater than those for syndecan-1. A sensitivity analysis excluding patients with AKI on arrival demonstrated the same relationship. CONCLUSIONS: Elevated sTM and syndecan-1, indicating endothelial dysfunction, were associated with higher incidence, worsened severity, and prolonged duration of AKI after severe trauma. Treatments that stabilize the endothelium hold promise for AKI treatment in severely injured patients.
Authors: Theis S Itenov; Jens-Ulrik Jensen; Sisse R Ostrowski; Pär I Johansson; Katrin M Thormar; Jens D Lundgren; Morten H Bestle Journal: Shock Date: 2017-06 Impact factor: 3.454
Authors: Ernesto Lopez; Zhanglong Peng; Rosemary A Kozar; Yanna Cao; Tien C Ko; Charles E Wade; Jessica C Cardenas Journal: Shock Date: 2020-02 Impact factor: 3.454
Authors: Erika Gonzalez Rodriguez; Sisse R Ostrowski; Jessica C Cardenas; Lisa A Baer; Jeffrey S Tomasek; Hanne H Henriksen; Jakob Stensballe; Bryan A Cotton; John B Holcomb; Pär I Johansson; Charles E Wade Journal: J Am Coll Surg Date: 2017-06-01 Impact factor: 6.113
Authors: Heather R Kregel; Gabrielle E Hatton; Kayla D Isbell; Hanne H Henriksen; Jakob Stensballe; Per I Johansson; Lillian S Kao; Charles E Wade Journal: Shock Date: 2022-01-01 Impact factor: 3.533
Authors: Joseph D Krocker; Kyung Hyun Lee; Hanne H Henriksen; Yao-Wei Willa Wang; Erwin M Schoof; Sigurdur T Karvelsson; Óttar Rolfsson; Pär I Johansson; Claudia Pedroza; Charles E Wade Journal: Int J Mol Sci Date: 2022-06-01 Impact factor: 6.208
Authors: Shannon C Walker; Robert P Richter; Lei Zheng; Amit R Ashtekar; Jan O Jansen; Jeffrey D Kerby; Jillian R Richter Journal: Shock Date: 2022-01-01 Impact factor: 3.454